NasdaqGM - Nasdaq Real Time Price • USD
Axsome Therapeutics, Inc. (AXSM)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 6:48 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 14 | 13 | 15 | 12 |
| Avg. Estimate | -1.21 | -1.03 | -3.86 | 1.03 |
| Low Estimate | -1.45 | -1.26 | -5.02 | -2.51 |
| High Estimate | -0.98 | -0.75 | -2 | 4.9 |
| Year Ago EPS | -0.26 | -1.54 | -5.27 | -3.86 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 14 | 14 | 16 | 15 |
| Avg. Estimate | 73.47M | 87.39M | 373.84M | 693.51M |
| Low Estimate | 65.7M | 80.5M | 339.58M | 538.95M |
| High Estimate | 84.76M | 95M | 442.8M | 942.55M |
| Year Ago Sales | 26.07M | 40.93M | 270.6M | 373.84M |
| Sales Growth (year/est) | 181.80% | 113.50% | 38.20% | 85.50% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -1.04 | -1.22 | -1.2 | -1.17 |
| EPS Actual | -0.26 | -1.54 | -1.32 | -2.08 |
| Difference | 0.78 | -0.32 | -0.12 | -0.91 |
| Surprise % | 75.00% | -26.20% | -10.00% | -77.80% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1.21 | -1.03 | -3.86 | 1.03 |
| 7 Days Ago | -1.18 | -1 | -3.77 | 1.13 |
| 30 Days Ago | -1.18 | -1.01 | -3.79 | 0.99 |
| 60 Days Ago | -1.2 | -1.04 | -3.77 | 0.57 |
| 90 Days Ago | -1.1 | -0.93 | -3.19 | 1.6 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | 1 |
| Up Last 30 Days | 2 | 1 | 2 | 2 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 2 | 2 | 2 | 1 |
Growth Estimates
| CURRENCY IN USD | AXSM | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -365.40% | -- | -- | 6.50% |
| Next Qtr. | 33.10% | -- | -- | 12.00% |
| Current Year | 26.80% | -- | -- | 5.30% |
| Next Year | 126.70% | -- | -- | 13.10% |
| Next 5 Years (per annum) | 187.90% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/10/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 4/2/2024 |
| Maintains | Mizuho: Buy to Buy | 3/28/2024 |
| Maintains | Truist Securities: Buy to Buy | 3/26/2024 |
| Maintains | RBC Capital: Outperform to Outperform | 3/26/2024 |
| Maintains | Citigroup: Buy to Buy | 3/26/2024 |
Related Tickers
TGTX TG Therapeutics, Inc.
13.47
-3.16%
MDGL Madrigal Pharmaceuticals, Inc.
193.33
-0.54%
IOVA Iovance Biotherapeutics, Inc.
11.64
+0.87%
LXRX Lexicon Pharmaceuticals, Inc.
1.5800
+2.60%
ALT Altimmune, Inc.
7.26
+0.83%
AVXL Anavex Life Sciences Corp.
3.4400
+1.47%
CYTK Cytokinetics, Incorporated
65.34
+0.83%
SAVA Cassava Sciences, Inc.
22.34
+2.81%
VKTX Viking Therapeutics, Inc.
74.31
+7.91%
ANVS Annovis Bio, Inc.
18.01
+32.43%